Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinkeshu is a traditional Chinese medicine (TCM) compound preparation widely used in China for the treatment of cardiovascular diseases, particularly coronary heart disease (CHD) and angina pectoris. It is composed of five herbal ingredients: *Crataegus pinnatifida* (Hawthorn), *Salvia miltiorrhiza* (Danshen), *Pueraria lobata* (Kudzu), *Panax notoginseng* (Sanqi), and *Dalbergia odorifera* (Jiangxiang). The formulation is recognized for its dual-effect in psychocardiology, addressing both the physiological symptoms of myocardial ischemia and the psychological symptoms of anxiety and depression often associated with heart disease. Its mechanisms include improving coronary blood flow, protecting the vascular endothelium, inhibiting platelet aggregation, and regulating the expression of eNOS and VCAM-1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xinkeshu.